CALRETICULIN V/S JAK2 MUTATION CHARACTERISTICS IN ESSENTIAL THROMBOCYTOSIS IN ASIAN AND NON-ASIAN POPULATION: A META-ANALYSIS
(Abstract release date: 05/21/15)
EHA Library. Kourie H. 06/12/15; 102744; PB1911
Disclosure(s): Jules Bordet InstituteHematology department
Hampig Raphael Kourie
Contributions
Contributions
Abstract
Abstract: PB1911
Type: Publication Only
Background
2014 was marked in myeloproliferative neoplasms by the discovery of Calreticuline mutation in essential thrombocytosis and primary myelofibrosis . Many papers were published describing the clinical, biological and epidemiological characteristics of this mutation compared to JAK2 mutation in ET. A meta-analysis of these studies was necessary to confirm the different characteristics of this new mutation in Asian and non-Asian populations.
Aims
The aim of this study is to evaluate the epidemiological, clinical and biological characteristics of patients with essential thrombosis having JAK2 or Calreticuline mutation and to compare the particularity of these mutations in Asian and non-Asian population .
Methods
8 studies published from December 2013 to October 2014 met the inclusion criteria of this meta-analysis: three of them in Asian population and five in non-Asian population. More than 2307 patients diagnosed having ET either with Calreticuline or JAK2 mutation were included. The epidemiological, clinical and biological characteristics of those patients at diagnosis (age, sex, hemoglobin level, white blood cells count, platelet counts, risk of thrombosis and hemorrhage, transformation to myelofibrosis or leukemia ) were compared according to the positivity of JAK2 or Calreticuline mutation and to the race (Asian and non-Asian) .
Results
The incidence of Calreticuline is 25% in ET patients in Asian and non-Asian subgroups. JAK 2 mutated ET patients are older than Calreticuline mutated patients with a mean difference of 6.9 years in all included patients, 5.3 years in Asians and 8.5 years in non-Asians. JAK2 mutated patients are less likely to be men when compared to calreticuline mutated patients in non-Asians with an OR =0.49; this OR was 1 in Asians. Hemoglobin level and white blood cell count was higher in JAK2 mutated patients compared to Calreticuline mutated patients in all sub-groups, while platelet count in JAK2 mutated patients was significantly lower. The risk of thrombosis was higher in JAK2 mutated patients compared to Calreticuline mutated patients at diagnosis and during the follow-up in all sub-populations with an OR>2 in all groups. The transformation to primary myelofibrosis was lower in JAK2 mutated patients, while there was no-significant difference in leukemia transformation, presence of splenomegaly at diagnosis and risk of hemorrhage.
Summary
With those specific characteristics, Calreticuline mutation will probably be added as diagnostic criteria of ET and will be considered a new prognostic factor affecting the treatment and the management of ET.
Keyword(s): Myeloproliferative disorder
Session topic: Publication Only
Type: Publication Only
Background
2014 was marked in myeloproliferative neoplasms by the discovery of Calreticuline mutation in essential thrombocytosis and primary myelofibrosis . Many papers were published describing the clinical, biological and epidemiological characteristics of this mutation compared to JAK2 mutation in ET. A meta-analysis of these studies was necessary to confirm the different characteristics of this new mutation in Asian and non-Asian populations.
Aims
The aim of this study is to evaluate the epidemiological, clinical and biological characteristics of patients with essential thrombosis having JAK2 or Calreticuline mutation and to compare the particularity of these mutations in Asian and non-Asian population .
Methods
8 studies published from December 2013 to October 2014 met the inclusion criteria of this meta-analysis: three of them in Asian population and five in non-Asian population. More than 2307 patients diagnosed having ET either with Calreticuline or JAK2 mutation were included. The epidemiological, clinical and biological characteristics of those patients at diagnosis (age, sex, hemoglobin level, white blood cells count, platelet counts, risk of thrombosis and hemorrhage, transformation to myelofibrosis or leukemia ) were compared according to the positivity of JAK2 or Calreticuline mutation and to the race (Asian and non-Asian) .
Results
The incidence of Calreticuline is 25% in ET patients in Asian and non-Asian subgroups. JAK 2 mutated ET patients are older than Calreticuline mutated patients with a mean difference of 6.9 years in all included patients, 5.3 years in Asians and 8.5 years in non-Asians. JAK2 mutated patients are less likely to be men when compared to calreticuline mutated patients in non-Asians with an OR =0.49; this OR was 1 in Asians. Hemoglobin level and white blood cell count was higher in JAK2 mutated patients compared to Calreticuline mutated patients in all sub-groups, while platelet count in JAK2 mutated patients was significantly lower. The risk of thrombosis was higher in JAK2 mutated patients compared to Calreticuline mutated patients at diagnosis and during the follow-up in all sub-populations with an OR>2 in all groups. The transformation to primary myelofibrosis was lower in JAK2 mutated patients, while there was no-significant difference in leukemia transformation, presence of splenomegaly at diagnosis and risk of hemorrhage.
Summary
With those specific characteristics, Calreticuline mutation will probably be added as diagnostic criteria of ET and will be considered a new prognostic factor affecting the treatment and the management of ET.
Keyword(s): Myeloproliferative disorder
Session topic: Publication Only
Abstract: PB1911
Type: Publication Only
Background
2014 was marked in myeloproliferative neoplasms by the discovery of Calreticuline mutation in essential thrombocytosis and primary myelofibrosis . Many papers were published describing the clinical, biological and epidemiological characteristics of this mutation compared to JAK2 mutation in ET. A meta-analysis of these studies was necessary to confirm the different characteristics of this new mutation in Asian and non-Asian populations.
Aims
The aim of this study is to evaluate the epidemiological, clinical and biological characteristics of patients with essential thrombosis having JAK2 or Calreticuline mutation and to compare the particularity of these mutations in Asian and non-Asian population .
Methods
8 studies published from December 2013 to October 2014 met the inclusion criteria of this meta-analysis: three of them in Asian population and five in non-Asian population. More than 2307 patients diagnosed having ET either with Calreticuline or JAK2 mutation were included. The epidemiological, clinical and biological characteristics of those patients at diagnosis (age, sex, hemoglobin level, white blood cells count, platelet counts, risk of thrombosis and hemorrhage, transformation to myelofibrosis or leukemia ) were compared according to the positivity of JAK2 or Calreticuline mutation and to the race (Asian and non-Asian) .
Results
The incidence of Calreticuline is 25% in ET patients in Asian and non-Asian subgroups. JAK 2 mutated ET patients are older than Calreticuline mutated patients with a mean difference of 6.9 years in all included patients, 5.3 years in Asians and 8.5 years in non-Asians. JAK2 mutated patients are less likely to be men when compared to calreticuline mutated patients in non-Asians with an OR =0.49; this OR was 1 in Asians. Hemoglobin level and white blood cell count was higher in JAK2 mutated patients compared to Calreticuline mutated patients in all sub-groups, while platelet count in JAK2 mutated patients was significantly lower. The risk of thrombosis was higher in JAK2 mutated patients compared to Calreticuline mutated patients at diagnosis and during the follow-up in all sub-populations with an OR>2 in all groups. The transformation to primary myelofibrosis was lower in JAK2 mutated patients, while there was no-significant difference in leukemia transformation, presence of splenomegaly at diagnosis and risk of hemorrhage.
Summary
With those specific characteristics, Calreticuline mutation will probably be added as diagnostic criteria of ET and will be considered a new prognostic factor affecting the treatment and the management of ET.
Keyword(s): Myeloproliferative disorder
Session topic: Publication Only
Type: Publication Only
Background
2014 was marked in myeloproliferative neoplasms by the discovery of Calreticuline mutation in essential thrombocytosis and primary myelofibrosis . Many papers were published describing the clinical, biological and epidemiological characteristics of this mutation compared to JAK2 mutation in ET. A meta-analysis of these studies was necessary to confirm the different characteristics of this new mutation in Asian and non-Asian populations.
Aims
The aim of this study is to evaluate the epidemiological, clinical and biological characteristics of patients with essential thrombosis having JAK2 or Calreticuline mutation and to compare the particularity of these mutations in Asian and non-Asian population .
Methods
8 studies published from December 2013 to October 2014 met the inclusion criteria of this meta-analysis: three of them in Asian population and five in non-Asian population. More than 2307 patients diagnosed having ET either with Calreticuline or JAK2 mutation were included. The epidemiological, clinical and biological characteristics of those patients at diagnosis (age, sex, hemoglobin level, white blood cells count, platelet counts, risk of thrombosis and hemorrhage, transformation to myelofibrosis or leukemia ) were compared according to the positivity of JAK2 or Calreticuline mutation and to the race (Asian and non-Asian) .
Results
The incidence of Calreticuline is 25% in ET patients in Asian and non-Asian subgroups. JAK 2 mutated ET patients are older than Calreticuline mutated patients with a mean difference of 6.9 years in all included patients, 5.3 years in Asians and 8.5 years in non-Asians. JAK2 mutated patients are less likely to be men when compared to calreticuline mutated patients in non-Asians with an OR =0.49; this OR was 1 in Asians. Hemoglobin level and white blood cell count was higher in JAK2 mutated patients compared to Calreticuline mutated patients in all sub-groups, while platelet count in JAK2 mutated patients was significantly lower. The risk of thrombosis was higher in JAK2 mutated patients compared to Calreticuline mutated patients at diagnosis and during the follow-up in all sub-populations with an OR>2 in all groups. The transformation to primary myelofibrosis was lower in JAK2 mutated patients, while there was no-significant difference in leukemia transformation, presence of splenomegaly at diagnosis and risk of hemorrhage.
Summary
With those specific characteristics, Calreticuline mutation will probably be added as diagnostic criteria of ET and will be considered a new prognostic factor affecting the treatment and the management of ET.
Keyword(s): Myeloproliferative disorder
Session topic: Publication Only
{{ help_message }}
{{filter}}